Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
GROWTH-INHIBITION AND CYTOTOXICITY INDUCED BY BOWMAN-BIRK INHIBITOR CONCENTRATE IN CISPLATIN-RESISTANT HUMAN OVARIAN-CANCER CELLS
Autore:
WAN XS; HAMILTON TC; WARE JH; DONAHUE JJ; KENNEDY AR;
Indirizzi:
UNIV PENN,SCH MED,DEPT RADIAT ONCOL PHILADELPHIA PA 19104 FOX CHASE CANC CTR,DEPT MED ONCOL PHILADELPHIA PA 19111
Titolo Testata:
Nutrition and cancer
fascicolo: 1, volume: 31, anno: 1998,
pagine: 8 - 17
SICI:
0163-5581(1998)31:1<8:GACIBB>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
C-MYC EXPRESSION; CARCINOMA CELLS; PROTEASE INHIBITOR; LUNG-CANCER; DNA-REPAIR; GENE-EXPRESSION; BREAST-CANCER; IN-VITRO; MECHANISMS; LINES;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
47
Recensione:
Indirizzi per estratti:
Citazione:
X.S. Wan et al., "GROWTH-INHIBITION AND CYTOTOXICITY INDUCED BY BOWMAN-BIRK INHIBITOR CONCENTRATE IN CISPLATIN-RESISTANT HUMAN OVARIAN-CANCER CELLS", Nutrition and cancer, 31(1), 1998, pp. 8-17

Abstract

Bowman-Birk inhibitor (BBI) is a soybean-derived anticarcinogenic protease inhibitor that was shown to potentiate the cytotoxicity of cisplatin in our previous studies. To assess the potential of BBI as a sensitizing agent for the chemotherapy of cisplatin-resistant cancers, we evaluated the effects of a soybean concentrate enriched in BBI (known as BBI concentrate or BBIC) on cell growth and clonogenic survival of a human ovarian cancer cell line, A2780, and its cisplatin-resistant sublines, C30 and C200. The presence of BBI and BBIC in the cell culture medium reduced the clonogenic survival of the A2780, C30, and C200 cells in a dose-dependent manner and enhanced cisplatin-induced growth inhibition and/or cytotoxicity. BBIC alone showed greater inhibitory effects on growth in the cisplatin-resistant cell lines. These results suggest that BBI and BBIC could be useful agents for the treatment of cancers, especially with cisplatin, in tumors resistant to this important anticancer agent.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/09/20 alle ore 01:01:57